Skip to main content
Top
Published in: Familial Cancer 2/2009

01-06-2009

Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations

Authors: Daniel H. Kim, Beth Crawford, John Ziegler, Mary S. Beattie

Published in: Familial Cancer | Issue 2/2009

Login to get access

Abstract

A growing body of research describes cancers other than breast and ovarian in families with BRCA1/2 mutations, but the prevalence and characteristics of pancreatic cancer in these families has not been well described. This study was designed to: (1) estimate the prevalence of pancreatic cancer in BRCA1/2 positive families; (2) ascertain age of onset and gender distribution of pancreatic cancer in this cohort; and (3) compare age and gender characteristics of pancreatic cancer in BRCA1/2 positive families with those of the general population. Within the UCSF Cancer Risk Program cohort, 24/219 (11.0%) BRCA1 and 17/156 (10.9%) BRCA2 families had at least 1 individual with pancreatic cancer. In the 24 BRCA1 families, median age of diagnosis was 59 (range 45–80) in males, and 68 (range 38–87) in females (male:female ratio = 2.00). In the 17 BRCA2 families, median age of diagnosis was 67 (range 39–78) in males and 59 (range 46–81) in females (male:female ratio = 1.11). The SEER database, which describes cancer characteristics in a representative sample of the US population, reports a median age of 70 in males and 74 in females (male:female ratio = 0.96) over the same time period. Additionally, mean ages of diagnosis of pancreatic cancer in BRCA1/2 families differ significantly from the SEER mean (P = 0.0014 for BRCA1 and P = 0.011 for BRCA2 by unpaired t-test). Our findings suggest that families with early onset pancreatic cancer and features of hereditary breast and ovarian cancer should be considered for BRCA1/2 testing.
Literature
3.
go back to reference Antoniou AC, Pharoah PD, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42(7):602–603. doi:10.1136/jmg.2004.024133 PubMedCrossRef Antoniou AC, Pharoah PD, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42(7):602–603. doi:10.​1136/​jmg.​2004.​024133 PubMedCrossRef
4.
go back to reference Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed
6.
go back to reference van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719. doi:10.1136/jmg.2004.028829 PubMedCrossRef van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719. doi:10.​1136/​jmg.​2004.​028829 PubMedCrossRef
7.
go back to reference Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56(23):5360–5364PubMed Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56(23):5360–5364PubMed
10.
go back to reference Offit K, Levran O, Mullaney B et al (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95(20):1548–1551PubMed Offit K, Levran O, Mullaney B et al (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95(20):1548–1551PubMed
11.
go back to reference Lee R, Beattie M, Crawford B et al (2005) Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. Genet Test 9(4):306–312PubMedCrossRef Lee R, Beattie M, Crawford B et al (2005) Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. Genet Test 9(4):306–312PubMedCrossRef
12.
18.
go back to reference Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6(1):R8–R17. doi:10.1186/bcr658 PubMedCrossRef Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6(1):R8–R17. doi:10.​1186/​bcr658 PubMedCrossRef
20.
go back to reference Whittemore AS, Gong G, John EM (2004) Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 13(12):2078–2083PubMed Whittemore AS, Gong G, John EM (2004) Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 13(12):2078–2083PubMed
21.
go back to reference Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121(2):225–231. doi:10.1002/ijc.22817 PubMedCrossRef Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121(2):225–231. doi:10.​1002/​ijc.​22817 PubMedCrossRef
Metadata
Title
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations
Authors
Daniel H. Kim
Beth Crawford
John Ziegler
Mary S. Beattie
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-008-9220-x

Other articles of this Issue 2/2009

Familial Cancer 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine